A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma

(2015) L. Zhang et al.   CLINICAL CANCER RESEARCH

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumorsin vivo

(2015) Mythili Koneru et al.   OncoImmunology

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors

(2014) E. K. Moon et al.   CLINICAL CANCER RESEARCH

A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG–PEI–cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study

(2014) Ronald D. Alvarez et al.   GYNECOLOGIC ONCOLOGY

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice

(2012) D. Chinnasamy et al.   CLINICAL CANCER RESEARCH

Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy

(2012) Katharine M. Esselen et al.   GYNECOLOGIC ONCOLOGY

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

(2011) X. Wang et al.   BLOOD

IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression

(2011) M. Chmielewski et al.   CANCER RESEARCH

In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)

(2011) D.-G. Song et al.   CANCER RESEARCH

Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer

(2011) Edward J. Tanner et al.   GYNECOLOGIC ONCOLOGY

MUC16 as a Sensitive and Specific Marker for Epithelial Downgrowth

(2010) Vicky C. Pai   ARCHIVES OF OPHTHALMOLOGY

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase

(2009) Elmer B Santos et al.   NATURE MEDICINE

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

(2009) C. Carpenito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer

(2008) Ninke Leffers et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse

(2008) Ying Wang et al.   DIFFERENTIATION

Immunotherapy opportunities in ovarian cancer

(2008) Christina S Chu et al.   Expert Review of Anticancer Therapy

The Use of Intraperitoneal Triamcinolone Acetonide for the Management of Recurrent Malignant Ascites in a Patient with Non-Hodgkin's Lymphoma

(2008) Rodric P. Jenkin et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT